文献速递眼底病与葡萄膜炎

地塞米松植入剂联合阿柏西普对比阿柏西普单药治疗糖尿病性黄斑水肿:COED试验

DEXAMETHASONE IMPLANT AND AFLIBERCEPT COMBINATION THERAPY VERSUS AFLIBERCEPT MONOTHERAPY FOR DIABETIC MACULAR EDEMA: A Prospective, Comparative Trial (COED Trial).
PubMed 文献 · Retina · 2026-01-01

本前瞻性随机对照试验将50例糖尿病性黄斑水肿患者随机分为地塞米松植入剂联合阿柏西普组与阿柏西普单药组,按预设再治疗标准行pro re nata治疗,随访48周。联合组在48周时中心亚区视网膜厚度和最佳矫正视力变化与单药组无显著差异,但黄斑水肿消退更快,注射次数数值更低,白内障和眼压升高风险更高。

要点

  • 联合治疗与阿柏西普单药在48周解剖和视力结局相似。
  • 联合组黄斑水肿消退更快,中位差异12周(log-rank P=0.013)。
  • 联合组出现白内障加重和需药物治疗的眼压升高各3眼和2眼。

核心结论

  • 联合地塞米松植入剂与阿柏西普治疗糖尿病性黄斑水肿在48周时达到与阿柏西普单药相似的解剖和视力结局。
  • 联合治疗使糖尿病性黄斑水肿消退更快,但白内障和眼压升高风险更高。

研究设计与样本

  • 开放标签随机临床试验,纳入50例糖尿病性黄斑水肿患者,随机分配至地塞米松联合阿柏西普组或阿柏西普单药组,按预设再治疗标准行pro re nata治疗,每月监测最佳矫正视力、中心亚区视网膜厚度和不良事件至48周。

主要发现

  • 两组每次访视均显示中心亚区视网膜厚度降低,48周时中心亚区视网膜厚度自基线变化组间差异为-32.9 µm(95%CI -81.5至15.6,P=0.183),倾向联合组但无统计学显著性。
  • 48周时最佳矫正视力自基线变化组间差异为-3.3个字母(95%CI -9.2至2.5,P=0.266)。
  • 阿柏西普单药组注射次数(均值±标准差5.9±1.8)数值上高于联合组(4.9±1.5),研究期间单药组注射率高出90%(发生率比[95%CI]=1.9[0.9-4.0],P=0.081),无统计学显著性。
  • 联合治疗组达到糖尿病性黄斑水肿消退的时间更快(log-rank P=0.013),中位差异为12周(95%CI 0-24)。
  • 联合治疗组有3眼出现白内障加重、2眼出现需药物治疗的眼压升高。

临床怎么用

  • 对于糖尿病性黄斑水肿患者,地塞米松植入剂联合阿柏西普可作为加快水肿消退的选项,但需权衡白内障和眼压升高的风险。
  • 联合治疗未显著改善48周视力或中心亚区视网膜厚度,注射次数减少无统计学意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare combined dexamethasone implant and intravitreal aflibercept (AFB) to AFB monotherapy treatment in diabetic macular edema (DME). METHODS: This open-label randomized clinical trial involved randomization of patients with DME (n = 50) to pro re nata treatment with combined dexamethasone and AFB or AFB alone according to prespecified retreatment criteria. Best-corrected visual acuity, central subfield retinal thickness (CST), and adverse events were monitored monthly for 48 weeks. RESULTS: The combined treatment and the AFB monotherapy group demonstrated CST reductions at each visit. The difference (95% confidence intervals [CI]) in the change from baseline in CST between the groups was -32.9 (-81.5 to 15.6) µ m at week 48, favoring the combination therapy group without significance ( P = 0.183). The difference in the change from baseline in best-corrected visual acuity was -3.3 (-9.2 to 2.5) letters read at week 48 ( P = 0.266). Injection number was numerically higher in the aflibercept monotherapy group (mean ± SD, 5.9 ± 1.8) than in the combination group (4.9 ± 1.5). The AFB monotherapy group had a 90% higher injection rate over the study period (incidence rate ratio [95% CI] = 1.9 [0.9-4.0]) without statistical significance ( P = 0.081). The combined treatment group achieved quicker time to resolution of DME (log-rank P -value = 0.013) by a median difference (95% CI) of 12 (0-24) weeks. Three eyes and two eyes in the combined therapy group developed worsening cataracts and intraocular pressure elevation requiring medical management, respectively. CONCLUSION: Combined treatment achieved similar anatomic and visual outcomes compared with AFB monotherapy, with quicker DME resolution but higher cataract and intraocular pressure risks.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Kim IP, Orndahl C, Nyaiburi C, et al. DEXAMETHASONE IMPLANT AND AFLIBERCEPT COMBINATION THERAPY VERSUS AFLIBERCEPT MONOTHERAPY FOR DIABETIC MACULAR EDEMA: A Prospective, Comparative Trial (COED Trial). Retina. 2026. PMID: 41954487. doi:10.1097/IAE.0000000000004858

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。